Long-Term Follow-Up of Bezafibrate Treatment in Patients With the Myopathic Form of Carnitine Palmitoyltransferase 2 Deficiency
- 26 May 2010
- journal article
- clinical trial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 88 (1) , 101-108
Abstract
Carnitine palmitoyltransferase 2 (CPT2) deficiency is a rare mitochondrial fatty acid oxidation (FAO) disorder characterized by myalgia, exercise intolerance, and rhabdomyolysis. We evaluate the efficacy of bezafibrate (BZ), a hypolipidemic drug, as a treatment for this form of CPT2 deficiency. A pilot trial was conducted with BZ in six patients for 6 months. There was a follow‐up period of 3 years. The oxidation rates of the long‐chain fatty acid derivative palmitoyl‐CoA, measured in the mitochondria of the patients' muscles, were markedly lower than normal before treatment and increased significantly (+39 to +206% P = 0.028) in all patients after BZ treatment. The evaluation of the therapeutic effects by the patients themselves (using the Short Form Health Survey (SF‐36)), as well as by the physicians, indicated an improvement in the condition of the patients; there was an increase in physical activity and a decline in muscular pain. The results suggest that BZ has a therapeutic effect in the muscular form of CPT2 deficiency. Clinical Pharmacology & Therapeutics (2010) 88 1, 101–108. doi: 10.1038/clpt.2010.55Keywords
This publication has 32 references indexed in Scilit:
- Mitochondrial fatty acid oxidation defects—remaining challengesJournal of Inherited Metabolic Disease, 2008
- Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese MenDiabetes, 2008
- Genetic Basis for Correction of Very-Long-Chain Acyl–Coenzyme A Dehydrogenase Deficiency by Bezafibrate in Patient Fibroblasts: Toward a Genotype-Based TherapyThe American Journal of Human Genetics, 2007
- PPARα-activation results in enhanced carnitine biosynthesis and OCTN2-mediated hepatic carnitine accumulationBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2007
- Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disordersEuropean Journal of Neurology, 2006
- A mitochondrial tRNA aspartate mutation causing isolated mitochondrial myopathyAmerican Journal of Medical Genetics Part A, 2005
- Roles of peroxisome proliferator-activated receptor delta (PPARδ) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndromeBiochimie, 2004
- Regulation of Muscle Fiber Type and Running Endurance by PPARδPLOS Biology, 2004
- Peroxisome proliferator‐activated receptors (PPARS): regulators of gene expression in heart and skeletal muscleActa Physiologica Scandinavica, 2003
- Validation of a French-language version of the MOS 36-Item Short Form Health Survey (SF-36) in young healthy adultsJournal of Clinical Epidemiology, 1995